The VES-13, a brief frailty screening tool, was found effective in determining which older patients with GU cancer were at higher risk for adverse outcomes and would benefit from a CGA.
Patients with GU malignancies were more likely to receive palliative care if they were in the West compared with other US regions.
Nadofaragene firadenovec, a novel gene-mediated therapy, achieved a 53.4% complete response rate in patients with high-grade carcinoma in situ unresponsive to bacillus Calmette-Guérin, phase 3 trial results show.
Toxicity profile and readmission rates among patients who underwent radical cystectomy and pelvic lymph node dissection following neoadjuvant pembrolizumab are in line with previously published series reporting 90-day outcomes after RC with or without neoadjuvant chemotherapy.
The Food and Drug Administration (FDA) has approved Keytruda (pembrolizumab; Merck) for the treatment of patients with Bacillus Calmette-Guerin (BCG)-unresponsive, high-risk, non-muscle invasive bladder cancer with carcinoma in situ (CIS) with or without papillary tumors who are ineligible for or have elected not to undergo cystectomy.